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Phone: (689) 40. 416.468 / Email: mlormeau@ilm.pf   Papeete, Tahiti, April 24, 2018 
 
Dear Editor, 
Please find enclosed a manuscript entitled: “Ross River virus antibody prevalence in the Fiji 
Islands, 2013-2015” we submit for publication as a letter in “Emerging Infectious Disease” journal.  
Ross River virus (RRV, Alphavirus genus, Togaviridae family) is endemic to Australia where it 
causes ~5,000 cases of infection annually. Outside Australia, RRV outbreaks were reported during 1979-
1980 in several Pacific countries including the Cook Islands, American Samoa, New Caledonia, Wallis and 
Futuna, and the Fiji Islands. Although RRV has not been locally detected in those countries after 1980, cases 
of RRV infection were reported in travelers returning from Fiji between 1997 and 2009. 
To investigate the possible undetected endemic circulation of RRV in Fiji, blood samples collected 
as part of a previous typhoid/leptospirosis seroprevalence study in 2013, and samples re-collected from a 
subset of the same participants in 2015, were tested for the presence of anti-RRV IgG antibodies. Among the 
participants who were born after 1982 (post-outbreak), 37.4% and 29.6% were seropositive for anti-RRV 
antibodies in 2013 and 2015, respectively. Moreover, 10.9% of the participants who had no detectable anti-
RRV antibodies in 2013 had seroconverted to RRV by 2015.  
Our findings confirm the continuous silent transmission of RRV in Fiji after 1980, and at least until 
2015. In addition to previous serosurveys conducted in American Samoa in 2010 and in French Polynesia 
during 2011-2013 and 2014-2015, the present study strongly supports the endemic circulation of RRV in the 
Pacific region during the past decades without the need of marsupials as main reservoirs, and raises 
questionings on the potential for RRV to emerge in other parts of the world.  
Please consider that this manuscript has not been submitted or accepted for publication elsewhere. 
We hope you will find our work of interest and our manuscript suitable for publication in Emerging 
Infectious Disease. 
Yours sincerely 
Van-Mai Cao-Lormeau 
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Abstract – 49 words  28 
A unique outbreak of Ross River virus (RRV) infection was reported in Fiji in 1979. In 2013, 29 
RRV seroprevalence among residents was 46.5%. Of those born after 1982, 37.4% had anti-RRV 30 
antibodies. Between 2013-2015, 10.9% of residents had seroconverted to RRV suggesting 31 
ongoing endemic circulation of RRV in Fiji. 32 
  33 
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Text - 797 words 34 
Ross River virus (RRV) is an Alphavirus of the family Togaviridae and is transmitted to 35 
humans by Aedes (Ae.) and Culex (Cx.) mosquitoes, with marsupials considered as significant 36 
reservoirs (1). Clinical manifestations of RRV infections include fever, rash, and arthralgia which 37 
commonly last 30-40 weeks. RRV is endemic to Australia where it causes ~5,000 cases of 38 
epidemic polyarthritis annually, and to Papua New Guinea where incidence is unknown (2). 39 
Outbreaks of RRV infection were reported between 1979-1980 in Fiji, the Cook Islands, 40 
American Samoa, New Caledonia, and Wallis and Futuna (1,3,4). Subsequently, RRV infections 41 
were detected in travelers returning from Fiji between 1997-2009 (4).  42 
The Republic of Fiji comprises 322 islands distributed among 4 administrative divisions 43 
(Central, Western, Eastern and Northern) and has a population of ~830,000. Apart from RRV, the 44 
four serotypes of dengue virus were the only mosquito-borne viruses known to circulate in Fiji 45 
until the recent emergence of Zika and chikungunya viruses (5). We report evidence of endemic 46 
RRV circulation in Fiji based on the serological analysis of blood samples collected in 2013 and 47 
2015. 48 
   This study included 778 participants recruited between September-November 2013 from 49 
the Central, Western and Northern divisions for a typhoid/leptospirosis community-based 50 
serosurvey (6). Among the residents from the Central division who had participated in the 2013 51 
survey, 333 were re-bled during October-November 2015 including 311 whose serum sample 52 
collected in 2013 was available to test. All blood samples were tested for the presence of anti-53 
RRV IgG using a recombinant antigen-based microsphere immunoassay (7). Data were analyzed 54 
with GraphPad Prism 6.03 using the Fisher or Chi-square tests. P values <0.05 were considered 55 
significant. The study was approved by the Fiji National Health Research Ethics Review 56 
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Committee (FNRER/N°2015.114.NW & FNRER/N°2015.45.MC), the University of the South 57 
Pacific (FSTER/2015/10/Research Proposal Approval) and the London School of Hygiene & 58 
Tropical Medicine Observational Research Ethics Committee (6344 & 10207). 59 
The prevalence of anti-RRV antibodies among all 2013 participants was 46.5%, and was 60 
lower in the Central (38.1%) than the Western (58.6%, p<0.0001) and Northern (55.9%, 61 
p=0.0108) divisions (Table). The prevalence of anti-RRV antibodies among the participants 62 
sampled in the Central division in 2015 was similar (37.2%) to results from this division in 2013 63 
(38.1%). In 2013, 37.4% of the participants born after 1982 (post-outbreak) had anti-RRV 64 
antibodies and in 2015 this rate (26.9%) was not significantly different (p=0.0685). The 65 
prevalence of anti-RRV antibodies increased with age (p<0.0001 in 2013, p=0.0020 in 2015) and 66 
was higher in rural than in urban (p<0.0001 in 2013, p=0.0197 in 2015) and peri-urban areas 67 
(p=0.0060 in 2013). There was no difference between genders. Among the 311 participants with 68 
available serum samples collected in 2013 and 2015, 21 of the 192 (10.9%) participants who had 69 
no detectable anti-RRV antibodies in 2013 had seroconverted to RRV by 2015. 70 
 A serosurvey conducted after the RRV outbreak in Fiji in 1979 detected anti-RRV 71 
antibodies in 92% of the participants from the Western division (3). In the study reported here, 72 
which was conducted in 2013, anti-RRV antibody prevalence in the Western, Central and 73 
Northern divisions ranged from 38.1% to 58.6%, and 37.4% of the people born after 1982 had 74 
anti-RRV antibodies, suggesting that RRV circulated in all three divisions after the 1979 75 
outbreak. The report of RRV infection in travellers returning from Fiji between 1997-2009 (4), 76 
the observations that 10.9% of the participants in this study seroconverted to RRV between 2013-77 
2015 and the increase in the prevalence of anti-RRV antibodies with age, suggest endemic RRV 78 
transmission in Fiji.  79 
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 The finding that RRV seroprevalence was higher in rural than in urban and peri-urban 80 
environments suggests increased transmission risks in the rural areas, potentially due to (i) higher 81 
risk occupations of rural residents including farming and outdoor work, (ii) greater exposure 82 
related to rural housing or other environmental factors, and/or (iii) to the fact that non-domestic 83 
mosquito species in Fiji such as Ae. vigilax, Ae. polynesiensis, Ae. pseudoscutellaris, Ae. 84 
albopictus, and Cx. annulirostris may be more competent vectors of RRV than peridomestic 85 
mosquitoes such as Ae. aegypti (8).  86 
Serosurveys conducted in American Samoa in 2010 (1), in French Polynesia between 87 
2011-2013 (9) and 2014-2015 (7), and the present study in Fiji during 2013-2015 suggest that 88 
endemic circulation of RRV in the Pacific region continued, or re-commenced, after 1979-1980. 89 
These data provide further evidence for endemic transmission of RRV in areas where marsupials 90 
are absent (10). Due to extensive travel between Australia and the Pacific islands, it is plausible 91 
that RRV is repeatedly seeded into the Pacific region. Whether this plays an important role in 92 
perpetuating local transmission in the Pacific islands is unknown. As previously illustrated with 93 
Zika and chikungunya viruses, there is a risk for emerging arboviruses to be imported from the 94 
Pacific to other parts of the world and RRV could be the next unexpected threat. 95 
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Table. Prevalence of anti-Ross River virus antibodies in a representative subset of the Fijian 138 
population sampled during September-November 2013 (n=778) and October-November 2015 139 
(n=333). 140 
Variables 
No. seropositive / No. tested (% [95% CI]) 
2013 2015 
Birth year   
< 1982  197/336 (58.6 [53.4–63.9]) 68/144 (47.2 [39.6–55.7]) 
≥ 1982 165/441 (37.4 [32.9-42.1]) 56/189 (29.6 [23.2-36.7]) 
1982 – 1990  58/117 (49.6 [41.1–58.9]) 17/38 (44.7 [31.4–61.4) 
1991 – 2000  66/146 (45.2 [37.7–53.6]) 20/66 (30.3 [21.3–42.9]) 
2001 – 2010  40/170 (23.5 [18.1–30.7]) 19/83 (22.9 [15.8–33.5]) 
> 2011  1/8 (12.5 [0.3–52.7]) 0/2 (0.0 [0.0–84.2]) 
Gender   
Female 195/423 (46.1 [41.5–51.0]) 73/190 (38.4 [32.1–45.8]) 
Male 167/354 (47.5 [42.2–52.5]) 51/143 (35.7 [28.6–44.1]) 
Division   
Central 172/451 (38.1 [33.9–42.8]) 124/333 (37.2 [32.4–42.7]) 
Northern 33/59 (55.9 [44.1–68.7]) − 
Western 157/268 (58.6 [52.8–64.5]) − 
Zone   
Rural  189/344 (54.9 [49.8–60.3]) 52/113 (46.0 [37.5–55.6]) 
Periurban  55/135 (40.7 [33.2–49.5]) 27/77 (35.1 [26.0–46.8]) 
Urban 117/298 (39.3 [34.1–45.1]) 45/143 (31.5 [24.8–39.8]) 
Total 362/778* (46.5 [43.1–50.1]) 124/333 (37.2 [32.4–42.7]) 
* For one participant, information about age and gender were not available; for another 141 
participant, information about the zone of residence was not available. 142 
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